UBS raised the firm’s price target on Encompass Health (EHC) to $130 from $117 and keeps a Buy rating on the shares. “Solid” Q1 results led to a guidance raise, and tariffs are not expected to have an impact this year, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health price target raised to $135 from $116 at Truist
- Encompass Health price target raised to $125 from $110 at RBC Capital
- Encompass Health price target raised to $130 from $120 at Raymond James
- Encompass Health price target raised to $130 from $110 at Mizuho
- Encompass Health: Strong Performance and Strategic Expansion Drive Buy Rating